Thus, our team decided to investigate the effect of berberine (300 mg, three times a day, 2 weeks) besides standard therapy on the recovery of COVID-19 outpatients who were monitored on days 3, 7, and 14 after beginning the therapy for clinical symptom improvement, quantitative C-reactive protein (CRP), lymphopenia, complete blood count (CBC), and arterial oxygen level (SpO2). The gene discussed is CRP; the disease is lymphopenia.